Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.

Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.

The cardiovascular safety of inhaled long-acting β2-agonists (LABAs) in patients with chronic obstructive pulmonary disease (COPD) is a controversial problem. Certain studies have suggested that inhaled LABAs lead to an increased risk of cardiovascular events in patients with COPD. This meta-analysi...

Full description

Bibliographic Details
Main Authors:	Ning Xia, Hao Wang, Xiuhong Nie
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4574772?pdf=render

Similar Items

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
by: Mario Cazzola, et al.
Published: (2019-11-01)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
by: Oba Y, et al.
Published: (2014-05-01)

Exacerbations in COPD patients treated with Inhaled Corticosteroids/Long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: A “real – world” study
by: Diego Sangiorgi, et al.
Published: (2017-01-01)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
by: Meng-Ting Wang, et al.
Published: (2019-07-01)

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
by: Israel Silva Maia, et al.

Indacaterol: A novel, Inhaled Beta-2 agonist for COPD
by: Ved Prakash, et al.
Published: (2015-01-01)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
by: Lee SY, et al.
Published: (2016-11-01)

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combinations in COPD
by: Mohd Kashif Siddiqui, et al.
Published: (2019-12-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
by: Scichilone N, et al.
Published: (2014-11-01)

Combination long acting β agonists-inhaled corticosteroids versus dual bronchodilation: a real conflict?
by: Marco Candela
Published: (2014-10-01)

Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics
by: Marco Caminati, et al.
Published: (2020-04-01)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers
by: Wittbrodt ET, et al.
Published: (2018-12-01)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?
by: Marc Miravitlles, M.D., et al.
Published: (2018-07-01)

Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists
by: Nobuyuki Horita, et al.
Published: (2012-01-01)

Inhalation of a Short-Acting β2-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects.
by: Mais Ali-Saleh, et al.
Published: (2016-01-01)

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.
by: Hongxin Huang, et al.
Published: (2014-01-01)

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes
by: Bosnic-Anticevich S, et al.
Published: (2016-12-01)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
by: Li CX, et al.
Published: (2019-04-01)

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?
by: Masato Muraki, et al.
Published: (2017-01-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

The Effects of Inhaled β-Adrenergic Agonists in Transient Tachypnea of the Newborn
by: Esengul Keleş MD, et al.
Published: (2016-05-01)

Inhaled β2-agonists in asthma management: an evolving story
by: Diana Silva, et al.
Published: (2016-12-01)

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes [Corrigendum]
by: Bosnic-Anticevich S, et al.
Published: (2019-08-01)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2019-01-01)

The effect of adding long acting beta 2 agonists to inhaled corticosteroids versus increasing dose of inhaled corticosteroids in improving asthma control
by: Nisreen M. Nabil, et al.
Published: (2014-10-01)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
by: Jinping Zheng, et al.
Published: (2021-03-01)

ARE INHALED LONG-ACTING BETA-AGONISTS (LABA) REALLY HARMFUL IN ADULT ASTHMATICS?
by: TNEW CL, et al.
Published: (2008-01-01)

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
by: Rogliani P, et al.
Published: (2017-12-01)

COPD significantly increases cerebral and cardiovascular events in hypertensives
by: Maria Perticone, et al.
Published: (2021-04-01)

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β-adrenoceptor agonist, with formoterol in patients with asthma
by: Leif Bjermer, et al.
Published: (2013-10-01)

Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered a pressurized metered-dose inhaler
by: Cedric Van Holsbeke, et al.
Published: (2018-02-01)

Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta-analysis
by: CHEN Xiaohong
Published: (2013-09-01)

A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
by: Daniel&nbsp;E Hilleman, et al.
Published: (2009-06-01)

Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study
by: Yen-Fu Chen, et al.
Published: (2019-12-01)

Risk for cardiovascular events associated with long-acting inhaled bronchodilator in patients with chronic obstructive pulmonary disease
by: Hsiao-Chung Chao, et al.
Published: (2012)

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]
by: Rogliani P, et al.
Published: (2018-10-01)

Acute Impact of Inhaled Short Acting B-Agonists on 5 Km Running Performance
by: John Dickinson, et al.
Published: (2014-06-01)

Cannot write session to /tmp/vufind_sessions/sess_0g5nmcq4o1cfqe6q1sdih05h1r